Antiviral, Anti-inflammatory, and Antimicrobial Peptides and Antimicrobial Peptide Enhancing Factor
Tech ID: 20942 / UC Case 2004-043-0
Technology DescriptionUC San Diego researchers have discovered a potent peptide in skin with activity against viral infections. It is also a potent antimicrobial protein with activity against bacteria such as Staph. aureus that are resistant to conventional antibiotics. The antiviral and antimicrobial peptides are naturally occurring in epithelial surfaces such as the skin, lung, and gut, and exhibit several immune defense functions. The natural peptide antiviral has potential applications in limiting viral proliferation and augmenting the host immune response. Animal models deficient in this natural antiviral peptide show increased susceptibility to viral skin diseases and are prone to atopic dermatitis. The antimicrobial peptide exhibits an ability to inhibit destructive enzymes that may prevent proper wound healing. The invention also includes an enhancing factor that can stimulate the activity of the peptides.
ApplicationsTopical anti-viral therapy for viral skin diseases (vaccination-induced eczema vaccinatum, herpes, molluscum contagiosum, papilloma virus) or for those suffering from atopic dermatitis or systemic anti-viral therapy. A diagnostic kit could be developed allowing point of care determination of this deficiency prior to smallpox vaccination. No effective topical antiviral therapy exists currently. The natural protein antibiotic has potential applications in treating sepsis, osteomyelitis, acne, wounds, and systemic or local infections. This technology may also have applications in the environmental decontamination field.
Intellectual Property InfoSee patent application WO2005/040201; additional patents pending.
- Braff MH, Bardan A, Nizet V, Gallo RL. Cutaneous defense mechanisms by antimicrobial peptides. J Invest Dermatol. 2005 Jul;125(1):9-13.
- Lee PH, Ohtake T, Zaiou M, Murakami M, Rudisill JA, Lin KH, Gallo RL. Expression of an additional cathelicidin antimicrobial peptide protects against bacterial skin infection. Proc Natl Acad Sci U S A. 2005 Mar 8;102(10):3750-5.
- Braff MH, Hawkins MA, Di Nardo A, Lopez-Garcia B, Howell MD, Wong C, Lin K, Streib JE, Dorschner R, Leung DY, Gallo RL. Structure-function relationships among human cathelicidin peptides: dissociation of antimicrobial properties from host immunostimulatory activities. J Immunol. 2005 Apr 1;174(7):4271-8.
- Murakami M, Lopez-Garcia B, Braff M, Dorschner RA, Gallo RL. Postsecretory processing generates multiple cathelicidins for enhanced topical antimicrobial defense. J Immunol. 2004 Mar 1;172(5):3070-7.
- Braff MH, Di Nardo A, Gallo RL. Keratinocytes store the antimicrobial peptide cathelicidin in lamellar bodies. J Invest Dermatol. 2005 Feb;124(2):394-400.
- Murakami M, Dorschner RA, Stern LJ, Lin KH, Gallo RL. Expression and secretion of cathelicidin antimicrobial peptides in murine mammary glands and human milk. Pediatr Res. 2005 Jan;57(1):10-5.
- Bardan A, Nizet V, Gallo RL. Antimicrobial peptides and the skin. Expert Opin Biol Ther. 2004 Apr;4(4):543-9. Review.
- Howell MD, Jones JF, Kisich KO, Streib JE, Gallo RL, Leung DY. Selective killing of vaccinia virus by LL-37: implications for eczema vaccinatum. J Immunol. 2004 Feb 1;172(3):1763-7.
- Ong PY, Ohtake T, Brandt C, Strickland I, Boguniewicz M, Ganz T, Gallo RL, Leung DY. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N Engl J Med. 2002 Oct 10;347(15):1151-60.
- Conner K, Nern K, Rudisill J, O'Grady T, Gallo RL. The antimicrobial peptide LL-37 is expressed by keratinocytes in condyloma acuminatum and verruca vulgaris. J Am Acad Dermatol. 2002 Sep;47(3):347-50.
|United States Of America||Issued Patent||7,776,823||08/17/2010||2004-043|
|United States Of America||Issued Patent||7,718,618||05/18/2010||2004-043|
2004-043-0, 2003-114-1, 2003-114-2, 2003-079-1